Anne Estrup Olesen

Anne Estrup Olesen

Auto-generated profile, based on publicly available information

Anne Estrup Olesen

Department of Clinical Medicine Aalborg University Aalborg Denmark

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
ADAsbjørn M. Drewes
Asbjørn M. Drewes
AOAnne E. Olesen
Anne E. Olesen
AFAdam D. Farmer
Adam D. Farmer
ESEva Szigethy
Eva Szigethy
VRVinciane Rebours
Vinciane Rebours
SOSøren S. Olesen
Søren S. Olesen

1 October 2012 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
JOJessica O'NEill
Jessica O'NEill
CBChristina Brock
Christina Brock
AOAnne Estrup Olesen
Anne Estrup Olesen
TATrine Andresen
Trine Andresen
MNMatias Nilsson
Matias Nilsson
ADAnthony H. Dickenson
Anthony H. Dickenson
A large number of pharmacological studies have used capsaicin as a tool to activate many physiological systems, with an emphasis on pain research but also including functions such as the cardiovascular system, the respiratory system, and the urinary tract. Understanding the actions of capsaicin led to the discovery its receptor, transient receptor potential (TRP) vanilloid subfamily member 1 (TRPV1), part of the superfamily of TRP receptors, sensing external events. This receptor is found on key fine sensory afferents, and so the use of capsaicin to selectively activate pain afferents has been exploited in animal studies, human psychophysics, and imaging studies. Its effects depend on the dose and route of administration and may include sensitization, desensitization, withdrawal of afferent nerve terminals, or even overt death of afferent fibers. The ability of capsaicin to generate central hypersensitivity has been valuable in understanding the consequences and mechanisms behind enhanced central processing of pain. In addition, capsaicin has been used as a therapeutic agent when applied topically, and antagonists of the TRPV1 receptor have been developed. Overall, the numerous uses for capsaicin are clear; hence, the rationale of this review is to bring together and discuss the different types of studies that exploit these actions to shed light upon capsaicin working both as a tool to understand pain but also as a treatment for chronic pain. This review will discuss the various actions of capsaicin and how it lends itself to these different purposes.

1 July 2012 in Pharmacological Reviews
Verified
Journal Article
Open access
PDF file
AOAnne Estrup Olesen
Anne Estrup Olesen
TATrine Andresen
Trine Andresen
CSCamilla Staahl
Camilla Staahl
ADAsbjørn M. Drewes
Asbjørn M. Drewes
Pain models in animals have shown low predictivity for analgesic efficacy in humans, and clinical studies are often very confounded, blurring the evaluation. Human experimental pain models may therefore help to evaluate mechanisms and effect of analgesics and bridge findings from basic studies to the clinic. The present review outlines the concept and limitations of human experimental pain models and addresses analgesic efficacy in healthy volunteers and patients. Experimental models to evoke pain and hyperalgesia are available for most tissues. In healthy volunteers, the effect of acetaminophen is difficult to detect unless neurophysiological methods are used, whereas the effect of nonsteroidal anti-inflammatory drugs could be detected in most models. Anticonvulsants and antidepressants are sensitive in several models, particularly in models inducing hyperalgesia. For opioids, tonic pain with high intensity is attenuated more than short-lasting pain and nonpainful sensations. Fewer studies were performed in patients. In general, the sensitivity to analgesics is better in patients than in healthy volunteers, but the lower number of studies may bias the results. Experimental models have variable reliability, and validity shall be interpreted with caution. Models including deep, tonic pain and hyperalgesia are better to predict the effects of analgesics. Assessment with neurophysiologic methods and imaging is valuable as a supplement to psychophysical methods and can increase sensitivity. The models need to be designed with careful consideration of pharmacological mechanisms and pharmacokinetics of analgesics. Knowledge obtained from this review can help design experimental pain studies for new compounds entering phase I and II clinical trials.

1 October 2012 in Drugs
Verified
Journal Article
Closed access
PDF file
CBChristina Brock
Christina Brock
SOSøren Schou Olesen
Søren Schou Olesen
AOAnne Estrup Olesen
Anne Estrup Olesen
JFJens Brøndum Frøkjaer
Jens Brøndum Frøkjaer
TATrine Andresen
Trine Andresen
ADAsbjørn M. Drewes
Asbjørn M. Drewes

7 August 2009 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CSCamilla Staahl
Camilla Staahl
AOAnne Estrup Olesen
Anne Estrup Olesen
TATrine Andresen
Trine Andresen
LALars Arendt‐Nielsen
Lars Arendt‐Nielsen
ADAsbjørn M. Drewes
Asbjørn M. Drewes

1 July 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ESEva Sverrisdóttir
Eva Sverrisdóttir
TLTrine Meldgaard Lund
Trine Meldgaard Lund
AOAnne Estrup Olesen
Anne Estrup Olesen
ADAsbjørn M. Drewes
Asbjørn M. Drewes
LCLona Louring Christrup
Lona Louring Christrup
MKMads Kreilgaard
Mads Kreilgaard